1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Pharmaceutical Drug Delivery Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porters Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. Global Pharmaceutical Drug Delivery Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Route Of Administration
5.2.1.1. Oral Drug Delivery
5.2.1.2. Injectable Drug Delivery
5.2.1.3. Topical Drug Delivery
5.2.1.4. Ocular Drug Delivery
5.2.1.5. Nasal Drug Delivery
5.2.1.6. Transmucosal Drug Delivery
5.2.1.7. Implantable Drug Delivery
5.2.1.8. Other Drug Delivery
5.2.2. By Application
5.2.2.1. Infectious Diseases
5.2.2.2. Cancer
5.2.2.3. Cardiovascular Diseases
5.2.2.4. Diabetes
5.2.2.5. Respiratory Diseases
5.2.2.6. Central Nervous System Diseases
5.2.2.7. Auto Immune Diseases
5.2.2.8. Other
5.2.3. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. The Asia Pacific
5.2.3.4. Latin America
5.2.3.5. The Middle East and Africa
6. North America Pharmaceutical Drug Delivery Market
6.1. Market Size & Forecast by Value, 2018-2028
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Route Of Administration
6.2.2. By Application
6.2.3. By Country
6.2.3.1. United States
6.2.3.2. Canada
7. Europe Pharmaceutical Drug Delivery Market
7.1. Market Size & Forecast by Value, 2018-2028
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Route Of Administration
7.2.2. By Application
7.2.3. By Country
7.2.3.1. Germany
7.2.3.2. United Kingdom
7.2.3.3. Italy
7.2.3.4. France
7.2.3.5. Spain
7.2.3.6. Rest of Europe
8. The Asia Pacific Pharmaceutical Drug Delivery Market
8.1. Market Size & Forecast by Value, 2018-2028
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Route Of Administration
8.2.2. By Application
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. South Korea
8.2.3.5. Rest of Asia Pacific
9. Latin America Pharmaceutical Drug Delivery Market
9.1. Market Size & Forecast by Value, 2018-2028
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Route Of Administration
9.2.2. By Application
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Mexico
9.2.3.3. Rest of Latin America
10. The Middle East & Africa Pharmaceutical Drug Delivery Market
10.1. Market Size & Forecast by Value, 2018-2028
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Route Of Administration
10.2.2. By Application
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Impact of Covid-19 on Global Pharmaceutical Drug Delivery Industry
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
13.1. Novartis International AG
13.2. Pfizer INC
13.3. Johnson & Johnson
13.4. Hoffmann-LA Roche AG
13.5. Becton, Dickinson and Company
13.6. GlaxoSmithKline PLC
13.7. Merck & Co., INC
13.8. Sanofi
13.9. Bayer AG
13.10. 3M
13.11. Antares Pharma, INC
13.12. Amgen, INC
13.13. AbbVie INC
13.14. Genmab A/S
13.15. Gilead Sciences, INC
13.16. Boehringer Ingelheim
13.17. AstraZeneca PLC
13.18. Eli Lilly and Company
14. Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable